Advertisement
UK markets closed

  • FTSE 100

    8,285.71
    +99.36 (+1.21%)
     

  • FTSE 250

    21,356.30
    +471.95 (+2.26%)
     

  • AIM

    779.67
    +6.64 (+0.86%)
     

  • GBP/EUR

    1.1844
    -0.0006 (-0.05%)
     

  • GBP/USD

    1.2873
    +0.0019 (+0.14%)
     

  • Bitcoin GBP

    52,964.71
    +663.62 (+1.27%)
     

  • CMC Crypto 200

    1,375.17
    +44.56 (+3.35%)
     

  • S&P 500

    5,459.10
    +59.88 (+1.11%)
     

  • DOW

    40,589.34
    +654.27 (+1.64%)
     

  • CRUDE OIL

    76.44
    -1.84 (-2.35%)
     

  • GOLD FUTURES

    2,385.70
    +32.20 (+1.37%)
     

  • NIKKEI 225

    37,667.41
    -202.10 (-0.53%)
     

  • HANG SENG

    17,021.31
    +16.34 (+0.10%)
     

  • DAX

    18,417.55
    +118.83 (+0.65%)
     

  • CAC 40

    7,517.68
    +90.66 (+1.22%)
     
PROPERTY:

8 champion homes in Olympic host cities

A selection of properties in former Games cities as Paris 2024 starts

Biogen stock rises on Q1 results, Alzheimer's drug sales

Brad Smith
·Host

Shares of the biopharmaceutical company Biogen (BIIB) are on the rise Wednesday, buoyed by the company's first quarter results. The company beat profit expectations, driven by Biogen's cost-cutting initiatives and the boost in sales for its Alzheimer's drug, Leqembi.

Yahoo Finance's Anjalee Khemlani breaks down the details of the report.

For more expert insight and the latest market action, click here to watch this full episode of Morning Brief.

This post was written by Angel Smith